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There is increasing evidence to suggest that, in addition to their regenerative effect,
mesenchymal stromal cells (MSCs), and their secretome have an anti-inflammatory and
antimicrobial role in the innate immune response in conditions such as sepsis. However,
there is no published information on the effect of MSCs in bovine mastitis. Mastitis
often results in extensive tissue damage due to multi-microorganism co-infection. This
study investigated the ability of amniotic-derived conditioned medium (CM), in vitro
and in vivo, to counteract microbial action and restore healthy tissue capable of milk
production. Following determination of a dose–response curve, 10,000 colony-forming
units (CFU) of Staphylococcus aureus (S. aureus) were inoculated into bovine mammary
epithelial cell culture with and without 10% CM (supplemented either at the time of
bacteria inoculation or after 4 h). Acridine orange staining was used to assess cell
viability/apoptosis. Additionally, an in vivo study was performed using 48 dairy cows with
acute and chronic mastitis, treated with CM (treated group) or antibiotics (control group).
In vitro results showed that CM can attenuate bacterial growth, as evaluated by the
number of CFU. After 24 h of culture with S. aureus, 89.67% of mammary epithelial cells
treated with CM were still alive, whereas all cells cultured without CM were dead. Rates
of epithelial cell survival (60.67%) were similar when CM was added 4 h after bacteria
inoculation. There was no difference in somatic cell count between cases of acutemastitis
in the CM-treated or control group in the in vivo study. However, relapses in chronic
mastitis were less common in the group receiving CM. Our results show that CM is able
to mitigate bacterial growth in vitro and may be particularly useful in the treatment of
chronic mastitis, aiding restoration of milk production in cows that would otherwise be
removed from the production cycle.
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INTRODUCTION
Regenerative medicine relies on transplantation of mesenchymal
stromal cells (MSCs) for the treatment of pathology in both
human and veterinary medicine. However, engraftment of the
transplanted MSCs has only been documented in a few cases
(1–3). Indeed, only a small percentage of transplanted MSCs are
able to engraft and survive in the inhospitable environment of a
lesion (4–7). Recent data suggest that the action of transplanted
MSCs might involve the secretion of mediators that activate the
regenerative processes in the injured tissue. Conditionedmedium
(CM), secreted by cells during culture, has been demonstrated
to promote the structural and functional regeneration of cardiac
(6, 8), renal (5, 9), spinal cord (10), lung (11), and tendon (12)
tissues. Lange-Consiglio et al. (12) reported the process of healing
in tendons treated with CM to be comparable to that achieved by
the MSCs of origin. This suggests that the beneficial properties
of MSCs are attributable to paracrine stimulation of tissue-
resident stem cells. These effects may be ascribed to bioactive
factors known to suppress apoptosis and fibrosis, improve
angiogenesis, induce mitosis, promote stem cell differentiation,
and modulate the innate immune response (13). In addition
to releasing soluble factors into the CM, MSCs also release
non-soluble factors, such as extracellular microvesicles (MVs)
containing microRNAs. All these components can be considered
as essential intermediaries of cell-to-cell communication (14).
Thus, the substances produced by MSCs may be the main
mediators of their regenerative action. Pereira et al. (15) showed
that CM secreted by human cord blood cells has a high
concentration of soluble factors with proliferative, chemotactic,
and immunomodulatory action. The components of CM
included growth factors, cytokines, chemokines, amino acids
(valine, threonine, alanine, methionine, and glutamine), glucose,
and molecules with low molecular weight (lactate, acetate, and
pyruvate). Rossi et al. (16) identified soluble factors that had an
inhibitory action on the proliferation of T lymphocytes in CM
derived from cells isolated from human amniotic membrane and
suggested that prostaglandins might be responsible for this effect.
Although it is now recognized that the regenerative effects of
MSCs are mediated by paracrine stimulation of growth factors
secreted in CM, less is known about their antimicrobial action.
Some preclinical data indicate that MSCs and their secretome
Abbreviations: ACTB, actin B; ACTG1, actin G1; ALB, albumin; ADIPOQ,
adiponectin; AO, acridine orange; APOA1, apolipoprotein A1; APOA4,
apolipoprotein A4; APOE, apolipoprotein E; BME-UV cells, bovine epithelial
mammary cells; CBP2, carboxypeptidase B2; CCL5, chemokine ligand-5; CFU,
colony-forming units; CM, conditioned medium; CSN1S1, alpha-S1-casein; CTR,
control group; FBS, inactivated fetal bovine serum; F2, prothrombin; GM-CSF,
granulocyte macrophage colony-stimulating factor; HG-DMEM, high-glucose
Dulbecco’s modified Eagle’s medium; HPX, hemopexin; IGFBP5, insulin-like
growth factor-binding protein 5; IL-1β, interleukin-1 beta; IL-6, interleukin-6;
IL-8, interleukin-8; LPS, lipopolysaccharide; LS, linear score; LTF, lactoferrin;
MCP-1, monocyte chemoattractant protein-1; MSCs, mesenchymal stromal cells;
PI, propidium iodide; RPMI, Roswell Park Memorial Institute; S. aureus,
Staphylococcus aureus; SCC, somatic cells count; SD, standard deviation;
SERPINC1, antithrombin-III; THBS1, thrombospondin-1; SPARC, secreted
protein acidic and cysteine rich; TNF-α, tumor necrosis factor-alpha; TPM1,
tropomyosin alpha-1 chain.
have antimicrobial properties (17–19). Studies using models
of infection-induced organ damage have shown that MSCs
can exhibit antibacterial properties by the release of soluble
molecules, such as the peptides catelicidine LL-37 (20) and
lipocalin-2 (21), which lead to the clearance of bacteria. Park
et al. (22) demonstrated that MVs released by MSCs had an
antimicrobial effect in post-mortem perfused human lung with
severe bacteria pneumonia.
Bovine mastitis is an inflammatory process of the mammary
gland predominantly associated with a bacterial infection and it
is usually treated with intramammary antibiotics. Its effects on
mammary cell numbers and function result in altered mammary
secretion. The severity of the infection determines whether tissue
damage can be reversed with treatment, and milk production
comparable to that prior to the infection be regained. Therefore, a
therapeutic approach that is both antimicrobial and regenerative
would be ideal.
In view of the above, one aim of our study was to test the effects
of CM on epithelial mammary cells stressed by Staphylococcus
aureus (S. aureus). A further aim was to conduct a preclinical
study to evaluate the potential of the in vivo administration
of CM for regenerative based therapy of acute and chronic
bovine mastitis.
CM from amniotic cells was used. These cells represent an
intermediate state between embryonic and adult cells (23–26).
Cells from extra-fetal tissues possess a greater proliferative and
differentiative potential and have longer telomeres than cells
derived from adult tissues (27–29). Furthermore, they are able
to prevent fetal rejection due to their low immunogenicity
and their immunomodulatory characteristics (30). Secretomes
of amniotic derived cells have been shown to attenuate in
vitro lipopolysaccharide (LPS)-induced inflammation in equine
endometrial and tendon cells and in macrophages (31–33). These
characteristics represent a promising therapeutic option in many
inflammatory diseases.
METHODS
Chemicals, cell culture media, and supplements were obtained
from Sigma Aldrich, Milan, Italy, unless otherwise specified,
and tissue culture dishes were purchased from Euroclone,
Milan, Italy.
In vitro Study
Amniotic Membrane Collection, Cell Isolation, and
CM Production
Allanto-amniotic membranes were collected following standard
veterinary practice and in accordance with 2010/63 EU directive
on animal protection and Italian Law (D.L. No. 116/1992)
as previously described by Corradetti et al. (34). Briefly: the
allanto-amnion was kept at 4◦C and processed within 12 h.
The amniotic membrane was separated from its juxtaposed
allantois and cut into small pieces (about 9 cm2 each) that
were digested with 0.93 mg/ml collagenase type I and 20 mg/ml
DNAse (Roche, Mannheim, Germany) for∼3 h at 38.5◦C. Debris
were removed using a 100-mm cell strainer and released cells
were collected by centrifugation at 200×g for 10min. Amniotic
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cells (AMCs) were cultured in a medium composed of HG-
DMEM supplemented with 10% FBS, penicillin (100 UI/ ml)–
streptomycin (100 mg/ml), 0.25 mg/ml amphotericin B, 2mM
L-glutamine, and 10 ng/ml epidermal growth factor.
CM was obtained by culturing AMCs at passage 3 in ultra-
culture serum-free medium (Euroclone), without antibiotics, for
96 h without replacement of medium. The medium from each
flask was collected, pooled, centrifuged at 700×g to remove
cellular fragments, and kept at −80◦C. This method was carried
out for cells isolated from three placentas.
For the in vitro and the in vivo experiments, the CM was
lyophilized and preserved at 4◦C until use. Before use, the
CM was resuspended in sterile water to one-quarter of the
initial volume.
Epithelial Mammary Cell Culture
A conventional clonal cell line (BME-UV) from udder primary
epithelial cells (35) was used. These cells are known to synthesize
several milk components.
BME-UV cells were cultured in medium containing 40%
Ham F-12 nutrient mixture, 30% Roswell Park Memorial
Institute (RPMI) 1640 medium, 20% NCTC 135 (Gibco,
Paisley, UK), 10% fetal bovine serum, 0.1% lactalbumin
hydrolysate, 1.2mM glutathione, 1µg/ml hydrocortisone,
1µg/ml insulin, 0.1% lactose, 10µg/ml L-ascorbic acid, and
1% penicillin/streptomycin.
The cells were seeded onto 12-well plates at a density of 3 ×
103 cells/cm2 and cultured at 38.5◦C with 5% CO2. All trials were
performed on 80% of confluence.
Staphylococcus aureus and Dose–Response Curve
The S. aureus strain used in this in vitro study was isolated from
a clinical mastitis case. This strain is resistant to beta-lactams.
The spectrum of antibiotic sensitivity of the microorganism
was assessed by the VITEK R© 2 system using AST-GP79
test cards (BioMérieux, Marcy l’Étoile, France), following the
manufacturer’s instructions. Data on antibiotic sensitivity are
represented in Table 1.
The stress induced by S. aureus was evaluated by viability and
apoptotic staining on a dose–response curve in three replicates.
BME-UV cells were seeded at a density of 3 × 103 on 12-well
plates and S. aureus was inoculated at the rate of 100, 1,000, and
10,000 CFU/ml for 4–8, 12, and 24 h at 38.5◦C in 5% of CO2.
The concentration of CFU was assessed spectrophotometrically
and by serial dilution in order to verify the accuracy of the
inoculated quantities.
Staphylococcus aureus CM Treatment
BME-UV seeded at a density of 3 × 103 on 12-well plates with
1ml of culture medium were studied at different conditions:
(1) with S. aureus at a final concentration of 10,000 CFU/ml
(identified as the optimal concentration after dose–response
curve analysis); (2) with 10% CM; (3) with S. aureus and CM;
and (4) untreated (control group, CTR).
In condition 3 (S. aureus and CM), the CM was added either
concurrently with the bacterium at time 0 or after 4 h to allow
bacterial growth.
TABLE 1 | Spectrum of the antibiotic sensitivity of the Staphylococcus aureus
strain used for the in vitro assays.
Antimicrobial MIC Interpretation
Benzilpenicillin ≥0.5 R
Oxacillin ≤0.25 S
Cefalotin ≤2 S
Ceftiofur ≤0.5 S
Cefquinome ≤1 S
Amikacin ≤2 S
Gentamycin ≤0.5 S
Kanamycin ≤4 S
Neomycin ≤2 S
Enrofloxacin ≤0.5 S
Erythromycin ≥8 R
Tilmycosin ≥4 R
Tylosin ≥32 R
Clindamycin ≤0.12 S
Tetracycline ≤1 S
Florphenicol ≤4 S
Trimethoprim/Sulfametoxazol ≤10 S
MIC, Minimal inhibitory concentration; R, resistant; S, sensible.
In all conditions, cell culture was performed in a CO2
incubator at 38.5◦C for 24 h.
Each group was assessed at 4, 8, 12, and 24 h. At each time,
supernatants and cells were collected to evaluate bacteria count
and to perform viability and apoptotic staining.
Bacterial Count
At the end of each incubation time (4, 8, 12, and 24 h) and
for each experimental condition, supernatants were transferred
into sterile plastic tubes and 1ml was used for bacteria counts.
Bacteria counts were carried out by the standard dilutionmethod.
The supernatant (1ml) was diluted 10−7. For each dilution,
100 µl was inoculated on two plates of blood agar using the
spread method. After incubation at 37◦C overnight, the plate
with bacterial colonies between 15 and 150 were examined and
the colonies were counted. The data were expressed as CFU
per ml.
Viability and Apoptotic Staining
Staining was performed to classify cells as viable, apoptotic,
and necrotic as described in the literature (36). Staining was
performed using 1 µl of a solution of acridine orange (5mg in
1ml of ethanol) combined with 1 µl of propidium iodide and
1ml of phosphate buffer solution.
At each time point, the cells were detached with trypsin
and centrifuged at 250 × g for 10min. Fifty microliters of
pellet was diluted with 50 µl of dye. The analysis was carried
out immediately under fluorescence light microscopy (Olympus
BX51, Japan) at a magnification of 40×. Acridine orange dye
was excited at 460 nm while the emission wavelength was set
at 650 nm. Propidium iodide was excited at 535 nm while the
emission wavelength was set at 617 nm.
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Protein Identification in CM
Protein digestion was performed according to the filter-aided
sample preparation (FASP) protocol that combines both protein
purification and digestion (37, 38). Each biological sample
was run in quadruplicate. Briefly, reduction (DTT 8mM in
urea buffer −8M urea and 100mM Tris), alkylation (IAA
50mM in urea buffer −8M urea and 100mM Tris), and
digestion by trypsin at a final concentration of 0.01 µg/µl
(Promega Italia srl, Milan, Italy) were performed on filter
tubes (Nanosep centrifugal device with Omega membrane-
30K MWCO, Sigma-Aldrich). LC-MS analysis was performed
as previously described (39). First, 500 fmol/µl of digestion
of enolase from Saccharomyces cerevisiae (P00924) was added
to each sample as an internal standard, tryptic peptides were
separated, and then 0.25 µg of each digested sample was loaded
onto a Symmetry C18 5µm, 180µm × 20mm precolumn
(Waters Corp., Milford, MA, United States) and subsequently
separated by a 90-min reversed-phase gradient at 300 nl/min
(linear gradient, 2–85% CH3CN over 90min) using a HSS T3
C18 1.8µm, 75µm × 150mm nanoscale LC column (Waters
Corp.) maintained at 40◦C. The separated peptides were analyzed
on a high-definition Synapt G2-Si Mass spectrometer directly
coupled to the chromatographic system. Protein expression
was evaluated via a label-free ion mobility–enhanced data-
independent acquisition (DIA) proteomics analysis in expression
configuration mode (HDMSE). Processing of low and elevated
energy, added to the data of the reference lock mass [Glu1]-
Fibrinopeptide B Standard (Waters Corp.), provided a time-
aligned inventory of accurate mass-retention time components
for both the low- and the elevated-energy exact mass retention
time (EMRT). Protein quantification was performed using PLGS
3.03 (Waters Ltd., Newcastle upon Tyne). The samples were
automatically aligned according to retention time. The peak
processing method was performed in profile data mode and the
peptide ion detection method was set in high-resolution mode.
Database search was performed interrogating the UniProt B.
taurus reference proteome (proteome ID: UP000009136, 37513
protein entries, last release 21/09/2019). Peptide mass tolerance
was set to 10 ppm and fragment ion tolerance was set to 0.01 Da.
Carbamidomethyl cysteine and oxidation of methionine were
selected as fixed and variable modifications, respectively. The
search results were filtered to obtain a protein false discovery rate
(FDR) of 1%.
In vivo Study
Animals
Forty-eight Holstein Friesian cows enrolled for this study were
selected in two privately owned farms. In both farms, the animals
were divided into groups based on the lactation period and were
fed with a total mixed ration ad lib. Herd size varied from 150 to
200 cows in milk.
The farmers and the veterinarian enrolled in this study
identified milk alterations at milking time. After a detailed
clinical examination, the eligibility of the affected animal for the
study was assessed. Cows requiring systemic antibiotic treatment
were not enrolled in this study. Mastitis was classified as acute or
chronic based on clinical signs and milk analysis. Acute mastitis
was defined by the presence of abnormal milk (flakes and clots)
and clinical signs such as hot, swollen, and painful quarter.
In acute mastitis, milk production usually decreases and milk
composition is considerably altered (40).
In this study, chronicmastitis was diagnosedwhen the somatic
cell count (SCC) in the milk sample from the affected mammary
quarter was >500,000 for three consecutive months (41).
The animals were randomly allocated to four groups:
– Acute mastitis that was treated with intramammary antibiotic
(control group, CTR) (16 quarters/16 animals)
– Acute mastitis that was treated with intramammary CM (16
quarters/16 animals)
– Chronic mastitis that was treated with intramammary
antibiotic (CTR) (8 quarters/8 animals)
– Chronic mastitis that was treated with intramammary CM (8
quarters/8 animals)
Each udder quarter affected by mastitis was enrolled only once.
Indicators of udder inflammation
Somatic cells count. Somatic cell count was evaluated at different
time points: day 0, 7, 14, and 30 of treatment. The count was
performed with a DeLaval Cell counter DCC (Tumba, Sweden)
that performs fluorometric measurements. The somatic cell
count is expressed as a linear score (LS), which is a logarithmic
function that transforms the values of somatic cells into a
linear scale:
Linear Score = log2(n
◦cells : 100) + 3
Bacteriological analysis. The bacteriological assays were
performed on quarter milk samples collected before milking at
the start of the treatment (day 0) and at day 30 by an aseptic
procedure. Bacteriological analysis was performed by plating
milk on blood agar with esculine and Baird Parker RPF Agar.
The plates were incubated at 37◦C for 48 h, and the colonies were
identified by routine methods according to the National Mastitis
Council (42).
Intramammary administration of antibiotics or CM
All cows were treated after milking. CM was warmed to 38.5◦C
and inoculated intramammarily through the teat canal with a
syringe connected to a sterile disposable teat cannula. In the CTR
group, the antibiotic for local use, chosen on an antibiogram test,
was inoculated using the same procedure. Following inoculation,
the udder was gently rubbed with upwards movement of the
hands to distribute the product.
Three milliliters of CM alone or antibiotic alone was
administered twice daily, after milking, for three consecutive
days. The standard experimental volume of CM was set at 3ml
since, after lyophilization, CM was concentrated 4-fold, and
a uniform treatment protocol was needed to compare to the
antibiotic treatment.
After these treatments, an iodine teat-dip was performed.
In vivo results
An expert veterinarian defined clinical improvement when the
quarter and milk secretion subjectively returned to normal, and
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relapse was defined as a clinical mastitis that re-occurred from
the time of last examination (30 days after the treatment) until
the term of the same lactation. A quarter was considered clinically
recovered when clinical improvement occurred and an SCC value
at T30 reduced by at least 3 LS points compared to the value at T0.
Statistical Analysis
Data were analyzed by GraphPad Instat 3.00 for Windows
(GraphPad Software, La Jolla, CA, USA).
For in vitro study, all experiments were replicated three
times, and the data of viable, apoptotic, and necrotic epithelial
mammary cells, collected in different experimental conditions,
were expressed as percentages. Mean values and SEM of three
replications were compared using ANOVA.
For in vivo study, the between-subjects factor was represented
by treatments (2 levels) and the within-subjects factor was
represented by sampling time (4 levels) and the mixed-design
analysis of variance model was applied.
For all tests, differences were considered statistically
significant at p ≤ 0.05.
The ClueGO plugin v 2.5.5 (release 15.10.2019) for Cytoscape
3.7.2 (43) was used to obtain the ontology classification and
functional interaction networks for the proteins identified (44).
Functions associated with the groups were partitioned based on
significant functional associations between terms and protein
sets. Gene ontology (GO) categories and pathways that included
biological processes (BPs), molecular functions (MFs), and Kyoto
Encyclopedia of Genes and Genomes (KEGG) updated at the last
release (11.01.2018) were used. A two-sided hypergeometric test
with Bonferroni correction was used to select only significative
annotations with a p ≤ 0.05.
RESULTS
In vitro Study
Cell Isolation and CM Production
Amniotic cells were chosen for their ability to adhere to plastic.
Trypan blue exclusion assay showed an initial viability of AMCs
>90% and >80% for BME-VU cells. As a characteristic of MSC
phenotype, the AMCs at P3 express CD29, CD44, CD73, CD106,
CD105, Oct-4, c-Myc, and MHCI, and lack CD34 and MHCII.
Moreover, AMCs are able to differentiate into mesenchymal
(adipogenic, chondrogenic, and osteogenic differentiation) and
ectodermic lineages (neurogenic differentiation) as reported by
Corradetti et al. (34).
Cell Viability and Apoptosis
Figure 1A shows the different cell lines after staining for
viability. Viable cells appear with normal green-colored nuclei
and well-defined margins; apoptotic cells show green, or orange
chromatin and have membranes with buds; necrotic cells have
orange or red chromatin.
Dose–Response Curve
The dose–response curve of S. aureus on BME-UV cells
showed that maximum stress, as estimated by cell apoptosis
measurements, occurred with 10,000 CFU/ml and 24 h
incubation (Figure 1B). At this time, cells invaded by S. aureus
detached from the culture plate and appeared as brown clusters
in the culture media.
Treatment With S. aureus and CM
After evaluation of data obtained by the dose–response curve, all
in vitro experiments were performed with BME-UV cells in the
presence of 10,000 CFU/ml for 4, 8, 12, and 24 h at 38.5◦C in
5% CO2.
Results of the experiment of co-culture of cells and S. aureus
in the presence of 10% CM added at time 0 are shown in
Figures 2A,B for viability and apoptotic staining and for number
of CFUs. These results demonstrate that the inoculation of
Staphylococcus in the absence of CM induces cell death by 12 h. In
the presence of 10% CM, 89.67% of cells remain viable for 24 h in
culture. CM can attenuate bacterial growth; indeed, the bacterial
counts remained at lowest levels until 24 h compared to the S.
aureus alone.
The results of co-culture of cells and S. aureus in the presence
of CM added 4 h after bacterial inoculation are shown in
Figures 3A,B for viability and apoptotic staining and for number
of CFUs. These results demonstrate that, at 24 h, 60.67% of cells
with 10% of CM remain viable. When CM was added 4 h after
bacterial inoculation, bacterial counts increased to a level close to
108 CFU/ml only at 24 h.
The effects of S. aureus and CM on basal cell viability,
apoptosis, and necrosis were time-related and associated with
the time of addition of CM (0 or 4 h after the inoculation of S.
aureus). The same effects were observed for bacterial counts.
Protein Identification in CM
Forty-seven Bos taurus proteins were identified in the CM
(see Supplementary File 1). To obtain ontologies and
functions for the proteins, the entire list was analyzed with
the software ClueGO. Forty-three proteins were functionally
annotated to all the ontologies available and 22 were associated
with 35 representative terms and pathways after two-sided
hypergeometric test with Bonferroni correction. To provide
simple illustration of the most interesting terms and pathways
associated with this list, a ClueGO network representation
was produced (Figure 4). In this figure, we selected the most
significant GO BP terms (red to brown circles) associated with
several of the identified proteins (empty small circles). Eight
GO BP terms belong to functions important in explaining the
potential effect of CM during the in vitro and in vivo challenge.
In vivo Results
Somatic Cells Count and Bacteriological Assay
Forty-eight animals were enrolled in this study: 32 affected by
acute mastitis and 16 by chronic mastitis. The allocation of the
enrolled quarters into the two different experimental groups was
random. A list of the different species of bacteria identified is also
provided (Tables 2, 3).
Treatments
Table 4 shows the rate of quarters with a reduction of at least 3 LS
compared to the starting point and the rate of relapses.
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FIGURE 1 | Dose–response curve. Epithelial mammary cells were cultured with S. aureus inoculated at the rate of 100, 1,000, and 10,000 CFU/ml for 4, 8, 12, and
24 h. (A) Example of combined AO/PI staining. Under fluorescence microscopy, a viable cell showed green preserved chromatin; a necrotic cell showed orange-red
nuclei staining; an apoptotic cell showed green fragmented chromatin and budding of membrane. (B) Rate of viability, apoptosis, and necrosis.
There was no difference in the improvement of clinically
affected quarters treated with CM compared to antibiotic
treatment but the rate of relapses was numerically different.
Treatment with CM improved two quarters affected by
chronic mastitis.
Table 5 shows the values of the somatic cells expressed in LS
at the different time points for acute and chronic mastitis treated
with antibiotics or CM. At time 0 (T0), the average value of
SCC was 7.68 LS with a standard deviation (SD) of 0.30 in acute
mastitis and 8.40 LS with a SD of 0.18 in chronic mastitis. There
was no statistically significant difference between the antibiotic
group compared to CM groups but, in the antibiotic treatment,
the mean value of LS decreased constantly compared to the
CM treatments. Indeed, in both acute and chronic mastitis, the
reduction of LS values in the CM-treated group became evident
at the 14th day from the beginning of treatment compared to
the antibiotic alone in which the decrease started at the 7th
day. The results of both treatments (CM and the antibiotic)
were comparable.
DISCUSSION
In the present study, we hypothesized that the secretome
produced by amniotic-derived cells might have anti-
inflammatory roles that contribute to protection against
infection by S. aureus. In this context, we investigated the effect
of CM in an in vitro experiment on epithelial mammary cells
infected by S. aureus and in an in vivo study on cows with acute
and chronic mastitis. Mastitis is an inflammatory process of
the mammary gland that results, not only in decreased milk
production, but also in a reduction in milk quality. The action
of pathogens, mainly bacteria, and the consequent inflammatory
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FIGURE 2 | Co-culture of BME-UV cells and Staphylococcus aureus in the presence of 10% CM added at 0 h. (A) Rate of viability, apoptosis, and necrosis. (B)
Number of CFUs in the presence of CM or S. aureus alone. Mean values with a star (*) are significantly different from the rest within the same time point (P < 0.05).
process induce a change in the integrity and function of the
mammary epithelial cells with a resultant decrease in milk
production (45, 46). Therapy for mastitis (acute, chronic) and its
prevention (for dry cows) is mainly based on the use of antibiotics
but, in recent years, antibiotic resistance has been developing to
S. aureus, which is the most prevalent and contagious etiologic
agent in mastitis (47). Infections caused by these bacteria
are difficult to treat, mainly due to evolved mechanisms of
antimicrobial drug resistance and evasion of immune response
(48–50). Because of the growing number of antibiotic-resistant S.
aureus strains, there is an urgent need to investigate and develop
alternative therapeutics.
Bovine mammary epithelial cells constitute a physical barrier
and produce several antimicrobial substances and inflammatory
mediators such as tumor necrosis factor-alpha (TNF-α),
interleukin-1 beta (IL-1β), granulocyte macrophage colony-
stimulating factor (GM-CSF), interleukin-8 (IL-8), regulated on
activation normal T cell expressed and secreted (RANTES),
lactoferrin, serum amyloid A, and cyclooxygenase-2 (46, 51–53).
When severe, mastitis induces a decrease of α-lactalbumin and
caseinmRNAs and an increase inmRNA levels for several growth
factors previously cited. These results suggest the involvement
of growth factors in tissue protection or repair processes (54).
It seems that the mammary gland tries to regenerate itself and,
in this context, the use of CM which is rich in growth factors,
could help the regenerative process (as described in literature
for other injured tissues) (55–58). To date, however, there are
few documented reports of the antimicrobial properties of CM
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FIGURE 3 | Co-culture of BME-UV cells and S. aureus in the presence of 10% CM added at 0 h or 4 h. (A) Rate of viability, apoptosis, and necrosis. (B) Number of
CFUs in the presence of CM or S. aureus alone. Mean values with a star (*) are significantly different from the rest within the same time point (P < 0.05).
(19) and so, in this study, this was investigated in in vitro and in
vivo studies.
Our results show that CM is able to attenuate the proliferation
of S. aureus in BME-VU cells either when added at time 0 or, to a
lesser extent, when supplemented 4 h after the cells were exposed
to this bacterium. In the presence of S. aureus, all BME-VU cells
die within 12 h but when CM is added to the cell culture at the
same time as the bacteria or 4 h later, 89.67 or 60.67% of cells,
respectively, remain viable.
To confirm the ability of CM to counteract the proliferation
of S. aureus and to verify its regenerative effect, an in vivo study
was performed.
In vivo, the clinical diagnosis of mastitis is based on the
physical examination of milk and udder and, above all, according
to the recommendations of the International Dairy Federation
(IDF), on SCC and on themicrobiological status of themammary
quarter (59).
A positive bacterial culture was detected in 71.88% of animals
with acutemastitis, while bacterial culture was positive in all cows
with chronic mastitis.
Our results show that SCC values, expressed as LS, decreased
significantly (p ≤ 0.05) at 30 days of observation (T30) in both
mastitis groups, and no statistically significant differences were
observed between antibiotic and CM-treated quarters. However,
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FIGURE 4 | ClueGO cytoscape network of CM proteins associated with GO biological processes (GO BP) at medium network specificity. Colors of each circle
represent the significance level (red pV 0.005–0.05, light brown pV 0.0005–0.005) and the radius of the circle denotes the number of mapped genes/proteins (0–5).
Empty small circles represent the mapped proteins. Conversion Gene, protein respectively; LTF, lactoferrin; APOA4, apolipoprotein A4; F2, Prothrombin; ALB,
albumin; APOE, apolipoprotein E; ACTB, actin B; ACTG1, actin G1; CBP2, Carboxypeptidase B2; CSN1S1, Alpha-S1-casein; THBS1, Thrombospondin-1; APOA1,
apolipoprotein A1; ADIPOQ, Adiponectin; TPM1, Tropomyosin alpha-1 chain; IGFBP5, Insulin-like growth factor-binding protein 5; HPX, hemopexin; SERPINC1,
Antithrombin-III.
TABLE 2 | Allocation of enrolled quarters with acute mastitis into two experimental
groups and bacterial types cultured.
Quarters Total n
(%)
Antibiotic
(%)
CM
(%)
Total treated 32
(100)
16/32
(50)
16/32
(50)
Positive to bacterial growth 23
(71.88)
12/16
(75.00)
11/16
(68.75)
Microorganism
Aesculin-positive Streptococci 8/23
(34.78)
4/8
(50)
4/8
(50)
Coagulase-negative
Staphylococci
6/23
(26.09)
3/6
(50)
3/6
(50)
Escherichia coli 4/23
(17.39)
2/4
(50)
2/4
(50)
Streptococcus dysgalactiae 3/23
(6.79)
1/3
(25.00)
2/3
(75.00)
S. aureus 1/23
(4.35)
1
(100)
–
Others 1/23
(4.35)
1
(100)
–
the CM group had a lower rate of relapses. Indeed, mastitis did
not recur in any of the quarters after CM treatment.
The reduced recurrence rate in the CM group compared to
the antibiotic group and the improvement of the quarters affected
by chronic mastitis could be explained by the presence of growth
TABLE 3 | Allocation of enrolled quarters with chronic mastitis into two
experimental groups and bacterial types cultures.
Quarters Total n
(%)
Antibiotic
(%)
CM
(%)
Total treated and positive for
bacterial growth
16
(100)
8/16
(50)
8/16
(50)
Microorganism
Aesculin-positive Streptococci 8
(50.00)
4/8
(50.00)
4/8
(50.00)
S. aureus 8
(50.00)
4/8
(50.00)
4/8
(50.00)
factors in the CMwith both regenerative and antibacterial effects.
In fact, the number of quarters with positive evolution was higher
in the CM-treated group compared to the antibiotic one.
Our proteomic study identified some BP terms associated
with several identified proteins: in particular, the “negative
regulation of inflammatory response” and “regulation of TNF
production” could contribute via the action of the associated
protein adiponectin (ADIPOQ), thrombospondin-1 (THBS1),
lactoferrin (LTF), apolipoprotein E (APOE), apolipoprotein A1
(APOA1), and prothrombin (F2) to decrease TNF production
and inflammation during the challenge with S. aureus. The
presence of the term “killing of cells of other organism”
associated with LTF, albumin (ALB), and F2 proteins suggests
an antibacterial effect mediated mainly by F2 and LTF.
The “endothelial cell proliferation” as well as “regulation of
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TABLE 4 | Somatic cells count values and rate of relapse for each treatment, and clinical distinction between acute and chronic mastitis.
Mastitis Treatment N◦ treated
quarters
N◦ quarters
with >3 LS
(%)
N◦ quarters with
improvement
<3 LS
(%)
No. of quarters with
improvement that
relapsed <3 LS
(%)
N◦ quarters with
improvement < 3 LS
without relapse
(%)
ACUTE Antibiotic 16 7/16
(43.75)a
9/16
(56.25)a
6/9
(66.67)a
3/9
(33.33)a
CM 16 8/16
(50.00)a
8/16
(50.00)a
0/8
(00.00)b
8/8
(100)b
CHRONIC Antibiotic 8 8/8
(100.00)A
0/8
(0.00)A
0/8
(0.00)A
0/8
(0.00)A
CM 8 6/8
(75.00)A
2/8*
(25.00)A
0/8
(0.00)A
2/8 (100.00)A
Different small letter superscripts (a,b) in the same column indicate statistically different comparisons (p < 0.05) between acute mastitis.
Different capital letter superscripts (A,B) indicate statistically different comparisons (p < 0.05) between chronic mastitis.
*Two animals affected by chronic mastitis due to Staphylococcus aureus.
TABLE 5 | Mean values of the linear scores on days 0, 7, 14, and 30 in cows with acute and chronic mastitis treated with antibiotic or CM.
Mastitis Treatment Day 0 Day 7 Day 14 Day 30
Acute Antibiotic 7.46 ± 1.33aA 6.83 ± 1.69aA 5.92 ± 3.12aA 4.37 ± 2.66bA
CM 7.89 ± 1.11aA 7.63 ± 1.45aA 6.78 ± 1.28aA 4.75 ± 2.22bA
Chronic Antibiotic 8.27 ± 0.45aA 6.48 ± 1.31bA 6.59 ± 1.03bA 6.28 ± 0.77bA
CM 8.52 ± 1.12aA 7.98 ± 1.26aA 7.08 ± 1.21aA 6.11 ± 1.15bA
Different small letter superscripts (a,b) in the same line indicate significantly different comparisons (p ≤ 0.05) within the same treatment at different days in acute or chronic mastitis.
Different capital letter superscripts (A,B) in the same column indicate significantly different comparisons (p ≤ 0.05) among treatments in acute or chronic mastitis.
smooth muscle cell proliferation” may support a potential
regenerative effect at the cellular level by associated proteins
thrombospondin-1 (THBS1), insulin-like growth factor-binding
protein 5 (IGFBP5), ADIPOQ, tropomyosin alpha-1 chain
(TPM1) APOE, APOA1, and secreted protein acidic and cysteine
rich (SPARC). Oxidant detoxification and related proteins could
contribute to a decrease in oxidative stress and indirectly improve
cell viability. The term platelet activation may be related to the
release of proteins into the CM during growth. Taken together,
all the functions and the related proteins associated with the CM
support an anti-inflammatory, anti-bacterial, and proliferative
effect of CM.
Many studies have confirmed the antimicrobial effects of
CM. Studies using models of infection-induced organ damage
have shown that MSCs have direct and indirect antimicrobial
properties through the release of soluble factors, such as the
peptide catelicidine LL-37 (20), lipocalin-2 (19, 21) and beta-
defense-2 (60), which lead to bacterial clearance.
Other anti-bacterial mechanisms of MSCs could include
tryptophan catabolism through indoleamine 2,3-dioxygenase
(61) or through increased phagocytosis (57–60). MSCs increase
macrophage phagocytosis of bacteria by inducing the phenotypic
transition of monocytes from type 1 to type 2 (21, 62–67).
In a mouse model with peritonitis induced by Pseudomonas
aeruginosa, MSCs reduced the number of colony-forming units
in the blood by increasing the phagocytic activity of monocytes
(66). In a mouse model of sepsis (ligation and perforation of
the caecum), bacterial colonies in the blood decreased in the
group of animals treated with MSCs. The authors speculate
that this effect can be explained by the call of neutrophils
within the vascular compartment mediated by IL-10 (68).
Equine MSCs from different tissue are able to express some
immunomodulatory genes such as monocyte chemoattractant
protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and
chemokine ligand-5 (CCL5), suggesting that respective cytokines
may help limit infection indirectly by recruiting and activating
immune cells (19).
The action of these growth factors, which attract neutrophils
andmacrophages, could help explain why the SCC remained high
throughout CM treatment in our study, decreasing only from
T14 and not at T7 as in the antibiotic treatment.
In summary, we suggest that CM contains growth factors
with tissue regenerative and antimicrobial action, as well as
chemokines, which could act, in synergy, to increase the
host non-specific immune mechanism, promoting angiogenesis,
fibroplasia, matrix deposition, and re-epithelialization.
CONCLUSION
The use of CM for the treatment of mastitis would minimize
the use of antibiotics, limiting antibiotic resistance, and avoiding
ineffective and expensive treatments. Moreover, chronic mastitis
cases are often not treated, and affected animals are culled from
the herd. If our preliminary findings are confirmed in a larger
study, it may be possible to restore milk production even in cows
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that would normally be destined to leave the production cycle.
The use of CM may have further economic advantages for the
effective recovery of the glandular tissue and most importantly
for the prevention of antibiotic residues in the milk. In our in
vitro experiment, secretome produced by amniotic-derived cells
had protective effects on epithelial mammary cells infected by
S. aureus. Finally, the use of CM avoids the risk of rejection
compared to the transplantation of original MSCs (69), but
further studies will be needed to fully clarify antimicrobial effects
of CM.
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